Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vegavit Cardio
- Development stage
- Unknown
- Lead developer
- Spey Medical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vegavit Cardio is an oral dietary supplement developed and marketed by SPEY for the management of dyslipidemia and mild to moderate hypercholesterolemia, as well as for reducing cardiovascular risk. It is formulated as a fixed-dose combination tablet containing 200 mg of *Monascus purpureus* fermented rice (red yeast rice) and 10 mg of policosanols. The red yeast rice component contains monacolin K, which is chemically identical to lovastatin and acts as a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, thereby blocking endogenous cholesterol synthesis. Policosanol, a mixture of long-chain aliphatic alcohols derived from sugarcane wax, complements this effect by activating AMP-activated protein kinase (AMPK), which downregulates HMG-CoA reductase activity and enhances the expression and processing of low-density lipoprotein (LDL) receptors. Together, these ingredients work synergistically to improve the blood plasma lipid profile and reduce oxidative stress.
- Brand names
- Vegavit Cardio
- Other names
- Monascus purpureus fermented rice + policosanolpolicosanol + red yeast ricered yeast rice + policosanol
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LDLR (Low-density lipoprotein receptor)
Beyond the preview
Go deeper on Vegavit Cardio.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vegavit Cardio.